ENTX
NASDAQ · Biotechnology
Entera Bio Ltd
$3.15
-0.07 (-2.17%)
Financial Highlights (FY 2026)
Revenue
157.5K
Net Income
-43,342,822
Gross Margin
—
Profit Margin
-27,235.7%
Rev Growth
-31.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 38.1% | 38.1% |
| Operating Margin | -27,450.0% | -24,705.1% | -24.8% | -21.3% |
| Profit Margin | -27,235.7% | -25,873.9% | -30.8% | -22.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 157.5K | 229.6K | 9.20M | 8.70M |
| Gross Profit | — | — | 3.50M | 3.31M |
| Operating Income | -43,246,377 | -56,720,692 | -2,286,472 | -1,856,846 |
| Net Income | -43,342,822 | -56,847,187 | -2,830,498 | -1,987,756 |
| Gross Margin | — | — | 38.1% | 38.1% |
| Operating Margin | -27,450.0% | -24,705.1% | -24.8% | -21.3% |
| Profit Margin | -27,235.7% | -25,873.9% | -30.8% | -22.8% |
| Rev Growth | -31.4% | -31.4% | +9.2% | +11.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 7.94M | 8.67M |
| Total Equity | — | — | 25.38M | 23.96M |
| D/E Ratio | — | — | 0.31 | 0.36 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -43,570,389 | -60,320,416 | -2,581,372 | -2,786,589 |
| Free Cash Flow | — | — | -3,568,526 | -2,022,520 |